Related Experiment Video

Updated: Oct 12, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Production and characterization of monoclonal and polyclonal antibodies against thyrotropin-releasing hormone

W Klootwijk1, L M Vaessen, B F Bernard

  • 1Department of Internal Medicine III, Erasmus University Medical School, Rotterdam, The Netherlands.

Hybridoma
|June 1, 1995
PubMed

In this article, two mouse monoclonal antibodies (83-7B5-A1 and 83-6B6-A10) and three rabbit polyclonal antibodies (1118, 8572, and 8577) directed against thyrotropin-releasing hormone (TRH; pGlu-His-Pro-NH2) are described. The anti-TRH antibodies were raised by immunization with a TRH-bovine serum albumin conjugate obtained by coupling of the CO2H group of pGlu-His-Pro-OH to NH2 groups in the protein. The monoclonal antibodies were produced by hybridoma clones obtained by the fusion of SP2/0 myeloma cells with spleen cells of an immunized BALB/c mouse. Both monoclonal antibodies were of the IgG1 (kappa) subclass. Characterization of the anti-TRH antibodies showed that in general they are specific for the pGlu-His moiety. The cross-reactivities for the TRH-like peptides [Glu1]TRH, [Glu2]TRH, and [Phe2]TRH are low, while alterations at the Pro-NH2 moiety of TRH are recognized to varying extents. The specificities of these antibodies are markedly different from those previously obtained using TRH coupled through the histidine residue to protein as the immunogen.

More Related Videos

Generation of Monoclonal Antibodies Against Natural Products12:15

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
The Thyroid Gland01:23

The Thyroid Gland

The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...